Distinct Outcomes in Patients with Different Molecular Subtypes of Inflammatory Breast Cancer

Overview

Journal Saudi Med J

Specialty General Medicine

Date 2014 Nov 17

PMID 25399208

Citations 12

Authors

Jingyu Zhou

Yi Yan

Lei Guo

Huiying Ou

Jian Hai

Chaojie Zhang

Zhaoyun Wu

Lili Tang

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine the outcome of patients with luminal A, luminal B, human epidermal growth factor receptor-2 (HER-2) positive, and triple negative molecular subtypes of inflammatory breast cancer (IBC) using a retrospective analysis.

Methods: This study was conducted between February 2004 and February 2010 in 3 different hospitals in China. The clinical outcomes, pathological features, and treatment strategies were analyzed in 67 cases of IBC without distant metastases. A chi-square test and one-way ANOVA were used to assess outcomes between different subtypes. Overall survival (OS) was analyzed using the Kaplan-Meier method and multivariate analysis was conducted using the Cox regression model.

Results: The 2-year OS rate was 55% for the entire cohort. Median OS time among patients with luminal A was 35 months, luminal B was 30 months, HER-2 positive was 24 months, and triple negative subtypes was 20 months, and were significantly different from each other (p=0.001). Using multivariate analysis, luminal A had 76% (p=0.037), luminal B had 54% (p=0.048), and HER-2 positive subtypes had 47% (p=0.032) decreased risk of death compared with the triple negative subtype. Furthermore, elevated Ki-67 labeling was associated with increased risk of death, while the surgical treatment significantly improved patient survival.

Conclusion: Breast cancer subtypes are associated with distinct outcomes in IBC patients. Patients that presented with triple negative IBC had poorer outcome than luminal A, luminal B, and HER-2 subtypes. These results indicate that IBC is a heterogeneous disease similar to the conventional breast cancer.

Citing Articles

Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study.

Parrish K, Thomas S, Cartwright S, van den Bruele A, Zasloff R, DiLalla G Ann Surg Oncol. 2024; 31(12):8057-8067.

PMID: 39158638 DOI: 10.1245/s10434-024-16026-w.

Characterization of Inflammatory Breast Cancer in Hispanic Women from Puerto Rico.

Quirindongo-Rivera C, Rullan-Varela V, Underill Z, Rivera M, Ortiz-Ortiz K, Martinez-Montemayor M J Cancer. 2022; 13(14):3495-3502.

PMID: 36484009 PMC: 9723992. DOI: 10.7150/jca.77108.

Toward precision medicine in inflammatory breast cancer.

Viale G, Marra A, Curigliano G, Criscitiello C Transl Cancer Res. 2022; 8(Suppl 5):S469-S478.

PMID: 35117125 PMC: 8798747. DOI: 10.21037/tcr.2019.05.04.

Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer.

Kida K, Hess K, Lim B, Iwase T, Chainitikun S, Valero V Cancers (Basel). 2020; 12(11).

PMID: 33114311 PMC: 7690918. DOI: 10.3390/cancers12113105.

The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients.

Yuan J, Ding N, Xiao Z Front Pharmacol. 2020; 11:537265.

PMID: 32973536 PMC: 7481481. DOI: 10.3389/fphar.2020.537265.

References

Falck A, Bendahl P, Chebil G, Olsson H, Ferno M, Ryden L . Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. Breast Cancer Res Treat. 2013; 140(1):93-104. DOI: 10.1007/s10549-013-2617-8. View

Schairer C, Li Y, Frawley P, Graubard B, Wellman R, Buist D . Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst. 2013; 105(18):1373-84. PMC: 3776263. DOI: 10.1093/jnci/djt206. View

Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E . Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 2008; 28(3B):1797-804. View

Selz J, Stevens D, Jouanneau L, Labib A, Le Scodan R . Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2012; 84(5):1123-32. DOI: 10.1016/j.ijrobp.2012.02.047. View

Dawood S, Merajver S, Viens P, Vermeulen P, Swain S, Buchholz T . International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2010; 22(3):515-523. PMC: 3105293. DOI: 10.1093/annonc/mdq345. View

Li J, Gonzalez-Angulo A, Allen P, Yu T, Woodward W, Ueno N . Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83. PMC: 3248766. DOI: 10.1634/theoncologist.2011-0196. View

Yerushalmi R, Woods R, Ravdin P, Hayes M, Gelmon K . Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11(2):174-83. DOI: 10.1016/S1470-2045(09)70262-1. View

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

Chen S, Chen C, Yu K, Zhou R, Shao Z . Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012; 19(9):3002-11. DOI: 10.1245/s10434-012-2318-2. View

10.

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

11.

Shanbhogue A, Karnad A, Prasad S . Tumor response evaluation in oncology: current update. J Comput Assist Tomogr. 2010; 34(4):479-84. DOI: 10.1097/RCT.0b013e3181db2670. View

12.

Ge X, Pan S, Zeng F, Tang Z, Wang Y . A simple Chinese risk score model for screening cardiovascular autonomic neuropathy. PLoS One. 2014; 9(3):e89623. PMC: 3951191. DOI: 10.1371/journal.pone.0089623. View

13.

Gong P, Wang Y, Liu G, Zhang J, Wang Z . New insight into Ki67 expression at the invasive front in breast cancer. PLoS One. 2013; 8(1):e54912. PMC: 3561452. DOI: 10.1371/journal.pone.0054912. View

14.

Levine P, Veneroso C . The epidemiology of inflammatory breast cancer. Semin Oncol. 2008; 35(1):11-6. DOI: 10.1053/j.seminoncol.2007.11.018. View

15.

Vermeulen P, van Golen K, Dirix L . Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer. 2010; 116(11 Suppl):2748-54. DOI: 10.1002/cncr.25169. View

16.

Chen F, Ou H, Wang S, Wu Y, Yan G, Tang L . Associations between body mass index and molecular subtypes as well as other clinical characteristics of breast cancer in Chinese women. Ther Clin Risk Manag. 2013; 9:131-7. PMC: 3617914. DOI: 10.2147/TCRM.S41203. View

17.

Edge S, Compton C . The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471-4. DOI: 10.1245/s10434-010-0985-4. View

18.

Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y . Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast. 2008; 17(5):523-7. DOI: 10.1016/j.breast.2008.04.002. View

19.

Van Laere S, Ueno N, Finetti P, Vermeulen P, Lucci A, Robertson F . Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res. 2013; 19(17):4685-96. PMC: 6156084. DOI: 10.1158/1078-0432.CCR-12-2549. View

20.

Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F . Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol. 2012; 23(10):2578-2584. DOI: 10.1093/annonc/mds062. View